Jiang T, et al. - Researchers analyzed data from 16 relevant studies involving 1700 patients to determine the utility of blood neutrophil-to-lymphocyte ratio (NLR) as a predictor as well as a prognosticator for overall survival (OS) or progression-free survival (PFS) in patients with non-small-cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors. They analyzed published data that provided hazard ratios (HRs) and 95% confidence interval (CI). Using Stata/MP 14.1, they computed pooled estimates of treatment outcomes. In this patient population, shorter PFS and OS were observed in relation to elevated blood NLR. This was indicative of a potential predictive and prognostic value of blood NLR in this clinical setting.